PE20000547A1 - COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION - Google Patents
COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTIONInfo
- Publication number
- PE20000547A1 PE20000547A1 PE1999000419A PE00041999A PE20000547A1 PE 20000547 A1 PE20000547 A1 PE 20000547A1 PE 1999000419 A PE1999000419 A PE 1999000419A PE 00041999 A PE00041999 A PE 00041999A PE 20000547 A1 PE20000547 A1 PE 20000547A1
- Authority
- PE
- Peru
- Prior art keywords
- phentholamine
- treatment
- sexual dysfunction
- fentholamine
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a)MESILATO DE FENTOLAMINA; b)UN INHIBIDOR DE 3`,5'-MONOFOSFATO DE FOSFODIESTERASA GUANOSINA CICLICA TIPO V (PDE cGMPV), SIENDO DE PREFERENCIA CITRATO DE SILDENAFILO, (6R, 12aR)-2,3,6,7,12,12a-HEXAHIDRO-2-METIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2'1':6,1]PIRIDO[3,4-b]INDOL-1,4-DIONA, (3S,6R,12aR)-2,3,6,7,12,12a-HEXAHIDRO-2,3-DIMETIL-6-(3,4-METILENDIOXIFENIL)-PIRAZINO[2',1':6,1]PIRIDO[3,4-b]-INDOL-1,4-DIONA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE UN PRIMER Y UN SEGUNDO AGENTE VASODILATADOR; EL PRIMER AGENTE ES UN AGENTE DE BLOQUEO ALFA-1 ADRENERGICO O ALFA-2 ADRENERGICO TAL COMO FENTOLAMINA, MESILATO DE FENTOLAMINA, CLORHIDRATO DE FENTOLAMINA, FENOXIBENZAMINA, TOLAZOLINA, DIBENAMINA, YOHIMBINA, TERAZOSINA, DOXAZOSINA, PRAZOSINA. LA COMPOSICION PUEDE SER UTIL PARA EL TRATAMIENTO DE LA DISFUNCION SEXUALREFERS TO A PHARMACEUTICAL COMPOSITION INCLUDING a) PHENTHOLAMINE MESILATE; b) AN INHIBITOR OF 3`, 5'-CYCLIC GUANOSINE PHOSPHODIESTERASE MONOPHOSPHATE TYPE V (PDE cGMPV), OF PREFERENCE SILDENAPHYL CITRATE, (6R, 12aR) -2,3,6,7,12,12a-HEXAHYDRO- 2-METHYL-6- (3,4-METHYLENEDIOXIPHENYL) -PYRAZINE [2'1 ': 6.1] PYRID [3,4-b] INDOL-1,4-DIONA, (3S, 6R, 12aR) -2 , 3,6,7,12,12a-HEXAHYDRO-2,3-DIMETHYL-6- (3,4-METHYLEDIOXYPHENYL) -PYRAZINE [2 ', 1': 6.1] PYRID [3,4-b] - INDOL-1,4-DIONA. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES A FIRST AND A SECOND VASODILATING AGENT; THE FIRST AGENT IS AN ALPHA-1 ADRENERGIC OR ALPHA-2 ADRENERGIC BLOCKING AGENT SUCH AS PHENTHOLAMINE, PHENTHOLAMINE MESYLATE, PHENTHOLAMINE HYDROCHLORIDE, PENOXYBENZAMINE, TOLAZOLINE, DIBENAMINE, PTHAZHIMBINE, TERAZHIMBINE, TERAZHIMBINE. THE COMPOSITION MAY BE USEFUL FOR THE TREATMENT OF SEXUAL DYSFUNCTION
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8164098A | 1998-05-20 | 1998-05-20 | |
US8297798A | 1998-05-21 | 1998-05-21 | |
US10651798A | 1998-06-29 | 1998-06-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000547A1 true PE20000547A1 (en) | 2000-07-15 |
Family
ID=27374039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999000419A PE20000547A1 (en) | 1998-05-20 | 1999-05-18 | COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU4068599A (en) |
PE (1) | PE20000547A1 (en) |
WO (1) | WO1999059584A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1161255A4 (en) * | 1999-03-08 | 2002-07-17 | Merck & Co Inc | Methods and compositions for treating erectile dysfunction |
NO20002097L (en) * | 1999-04-30 | 2001-10-26 | Lilly Icos Llc | Preparation items |
US6943166B1 (en) | 1999-04-30 | 2005-09-13 | Lilly Icos Llc. | Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
BRPI0003386B8 (en) | 2000-08-08 | 2021-05-25 | Cristalia Produtos Quim Farmaceuticos Ltda | homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
PL1912650T3 (en) | 2005-08-03 | 2018-01-31 | Sprout Pharmaceuticals Inc | Use of flibanserin in the treatment of obesity |
CA2626134C (en) | 2005-10-29 | 2013-12-24 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
JP2009541443A (en) | 2006-06-30 | 2009-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Flibanserin for the treatment of urinary incontinence and related diseases |
JP5793828B2 (en) | 2006-08-14 | 2015-10-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Formulation of flibanserin and method for producing the same |
EP2056797A2 (en) | 2006-08-25 | 2009-05-13 | Boehringer Ingelheim International GmbH | Controlled release system and method for manufacturing the same |
CL2008002693A1 (en) | 2007-09-12 | 2009-10-16 | Boehringer Ingelheim Int | Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2146249T3 (en) * | 1993-02-10 | 2000-08-01 | Bmra Corp Bv | PHARMACEUTICAL COMPOSITION TO TREAT THE IMPOTENCE CONTAINED BY AN ALPHA-1 INHIBITOR AND AN ALPHA-2 INHIBITOR. |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
-
1999
- 1999-05-17 AU AU40685/99A patent/AU4068599A/en not_active Abandoned
- 1999-05-17 WO PCT/US1999/007046 patent/WO1999059584A1/en active Application Filing
- 1999-05-18 PE PE1999000419A patent/PE20000547A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU4068599A (en) | 1999-12-06 |
WO1999059584A1 (en) | 1999-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000547A1 (en) | COMBINATION OF FENTHOLAMINE AND GMP CYCLIC PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | |
TR200200989T2 (en) | Pharmaceutically active compounds. | |
MA29885B1 (en) | 2-AMINO-7,8-DIHYDRO-6H-PYRIDO [4,3-D] PYRIMIDINE -5-ONES | |
IN2012DN06436A (en) | ||
NO20010743L (en) | Antiviral indoloxoacetyl-piperazine derivatives | |
TR200003039T2 (en) | Pirazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunctions | |
DK1646389T3 (en) | Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists | |
UY26383A1 (en) | "PHARMACEUTICALLY ACTIVE COMPOUNDS" | |
MY130681A (en) | Compositions and methods for treating female sexual dysfunction | |
MA28270A1 (en) | Pyrido [2,3-D] pyrimidine-2,4-diamines as PDE 2 inhibitors | |
CL2004002061A1 (en) | COMPOUNDS DERIVED FROM CONDENSED HETEROCICLES CONTAINING NITROGEN; PHARMACEUTICAL COMPOSITION; AND ITS USE AS AN ANTIVIRAL AGENT, INTEGRASA INHUBIDATOR AND AS AN ANTI-HIV AGENT. | |
PE20000702A1 (en) | INTRANASAL FORMULATIONS TO TREAT SEXUAL DISORDERS | |
WO2008071587A3 (en) | 2-(piperidin-4-yl)-4-phenoxy- or phenylamino-pyrimidine derivatives as non-nucleoside reverse transcriptase inhibitors | |
IL164491A0 (en) | Non nucleoside reverse transcriptase inhibitors | |
PE20010924A1 (en) | USEFUL PHOSPHODIESTERASE INHIBITING COMPOUNDS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | |
AR027464A1 (en) | OXAMIDS THAT ARE INHIBITORS OF INOSINE MONOPHOSPHATE DEHYDROGENASE (IMPDH) | |
BRPI0412327A (en) | pyrimidine-2,4-dione derivatives as gonadotropin releasing hormone receptor antagonists | |
WO2002000657A3 (en) | Condensed pyrazindione derivatives | |
PT102457A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE INHIBITOR OF PDE5 | |
CY1109087T1 (en) | IMIDAZO UNION [4,5-C] PYRIDINIS AND ANTI-VICTIVE METHOD | |
NO20002696L (en) | New compounds with cGMP-PDE inhibitor effect | |
AR038858A1 (en) | COMBINATION | |
YU6396A (en) | Combination of hiv protease inhibitor with other compounds for hiv infection treatment | |
ATE376422T1 (en) | DICLAZURIL CONTAINING ANTIPPROTOZOAL AGENTS | |
WO2001030329A3 (en) | Combinations of lamivudine and entecavir for treatment of hepatitis b virus infuction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |